© 2000 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Induction of IG9 Monocyte Adhesion Molecule Expression in Smooth Muscle and Endothelial Cells After Balloon Arterial Injury in Cholesterol-Fed Rabbits
From the Department of Pathology (T.M.C., J.W.B.) and Department of Microbiology and Immunology (J.W.B.), Albert Einstein College of Medicine, Bronx, NY; the Department of Anatomy and Cell Biology (S.D.G.), The Hebrew University, Hadassah Medical School, Jerusalem, Israel; the Cardiovascular Division (I.J.S.), The University of Virginia Health Sciences Center, Charlottesville, Va; the Departments of Pathology and Medicine (J.A.B.), University of California School of Medicine, Los Angeles; the Zena and Michael A. Wiener Cardiovascular Institute (J.T.F., M.B.T.), Department of Pathology (J.T.F.), and Department of Medicine (J.T.F., M.B.T.), Mount Sinai School of Medicine, New York, NY.
Correspondence to Tina M. Calderon, PhD, Albert Einstein College of Medicine, Department of Pathology F727, 1300 Morris Park Ave, Bronx, NY 10461. E-mail calderon{at}aecom.yu.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—The expression of monocyte-specific adhesion molecules and chemokines by cell types within the vessel wall plays an important role in foam cell accumulation during atherosclerotic plaque development. We previously identified IG9, a novel monocyte adhesion protein that is expressed on endothelial cells (ECs) overlying human and rabbit advanced atherosclerotic plaques. The present study was designed to determine the temporal and spatial expression of IG9 and the chemokine, monocyte chemoattractant protein-1 (MCP-1), after balloon injury with (double injury) or without (single injury) prior air desiccation EC injury in the femoral arteries of rabbits fed a high-cholesterol diet. By immunohistochemical analyses, intense reactivity with monoclonal antibodies to IG9 and MCP-1 was detected 24 hours after single injury in medial smooth muscle cells (SMCs) and in SMCs of adventitial microvessels. However, monocyte infiltration of the tunica media was minimal or not detected in these sections. IG9 and MCP-1 antibody reactivity in vessel sections 28 days after single injury and 24 hours, 7 days, and 28 days after double injury was localized to medial and neointimal SMCs, foam cells, and luminal ECs overlying the plaques. Uninjured rabbit (cholesterol or normal diet) vessel sections exhibited minimal IG9 and MCP-1 immunostaining. In vitro studies using human aortic SMCs demonstrated IG9 protein induction after 24 hours of treatment with platelet-derived growth factor-BB and interferon-
or epidermal growth factor. IG9 expression was further
increased by pretreatment of SMCs with the proatherogenic lipid,
minimally oxidized low density lipoprotein. After balloon injury (24
hours), IG9 is induced in vascular SMCs before the detectable
accumulation of monocytes within the vessel wall. Thus, the expression
of IG9 by SMCs as well as by ECs may be an important factor in the
accumulation of foam cells in atherosclerotic plaque development after
arterial injury.
Key Words: arterial injury • atherosclerosis • smooth muscle • adhesion molecules • LDL, minimally oxidized or modified
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The adherence of circulating monocytes to endothelial cells (ECs) is one of the earliest events in the development of atherosclerotic plaques.1 2 3 Injury to the vascular endothelium induces EC dysfunction and promotes an inflammatory response characterized by the adherence of monocytes and T lymphocytes to the vessel wall.1 2 3 4 On entering the subendothelial space, monocytes take up lipids, become activated, and release inflammatory and chemotactic molecules, including the cytokine, tumor necrosis factor-
(TNF-),5 6 and the chemokine, monocyte
chemoattractant protein-1 (MCP-1).7 8 Chemokine expression
contributes to the recruitment of additional monocytes (and T
lymphocytes) into the developing lesion, and inflammatory mediators
produced by the infiltrating leukocytes stimulate resident cells within
the vessel wall to secrete additional proatherogenic molecules,
including growth-regulatory factors, cytokines, and other
chemokines. These molecules promote medial smooth muscle cell (SMC)
migration and proliferation and the continued influx of monocytes and T
lymphocytes, thereby amplifying this inflammatory process and promoting
neointimal hyperplasia.3 9 An understanding of
the mechanisms involved in the initial recruitment and adhesion of
monocytes to the vessel wall and their subsequent retention within the
developing atherosclerotic lesion might facilitate the design of
interventional strategies to attenuate this process. Monocyte binding is mediated, in part, by the expression of adhesion proteins that are induced on the surface of ECs by a variety of stimuli, including cytokines.10 11 12 13 P-selectin,14 intercellular adhesion molecule-1 (ICAM-1),15 16 17 18 E-selectin,18 and vascular cell adhesion molecule-1 (VCAM-1)18 19 have been detected in human atherosclerotic vessels.
All of these adhesion proteins were found to be expressed by ECs, with VCAM-1 localized mainly to vessels within neovascularized areas of plaques19 and the other adhesion proteins expressed by luminal ECs overlying the plaques.14 15 16 17 18 ICAM-1 and VCAM-1 were also shown to be focally expressed by SMCs within plaques.15 16 18 19
We identified previously a novel monocyte adhesion molecule that is
recognized by monoclonal antibody (mAb) IG9 and is expressed on the
surface of activated ECs.20 The 105-kDa adhesion
molecule, referred to as the IG9 protein, is not expressed in vitro on
untreated human umbilical vein endothelial cells but is
induced after treatment with TNF-, interleukin-1ß,
lipopolysaccharide, or phorbol myristate
acetate.20 21 IG9 expression is first detected 3 hours
after treatment of human umbilical vein endothelial
cells with these agonists, and maximal levels are induced after 4 to 9
hours, returning to baseline after 48 hours. Minimally oxidized or
modified LDL (MM-LDL) also induces IG9 expression in human umbilical
vein endothelial cells and in human aortic ECs.
E-selectin, VCAM-1, and ICAM-1 are not induced or upregulated in
MM-LDL–treated ECs.22 Monocyte adhesion to TNF-– and
MM-LDL–treated ECs is significantly inhibited by mAb IG9, whereas
lymphocyte and granulocyte binding to TNF-–treated cultures is
unaffected.20
In human and rabbit advanced atherosclerotic plaques, IG9 protein
expression in vivo has been localized to arterial luminal
endothelium, suggesting a possible functional role for
this protein in monocyte adhesion to ECs overlying the plaques during
lesion progression.20 The present study examines the
cell type–specific expression of the IG9 adhesion molecule for
monocytes and the monocyte chemoattractant, MCP-1, after
balloon-induced arterial injury in the
cholesterol-fed rabbit models of single and double
injury.23 24 25 We found that IG9 and MCP-1 are prominently
expressed by medial SMCs very early after balloon injury (BI) and
before detectable monocyte infiltration of the tunica media. In cell
culture studies, SMCs were induced to express IG9 protein after
treatment with MM-LDL, platelet-derived growth factor (PDGF)-BB,
and either TNF- or epidermal growth factor (EGF) for 24 hours. Thus,
vascular SMC expression of IG9, in addition to MCP-1, may be a
significant contributor to the extensive accumulation of
macrophages within the vessel wall after arterial
injury.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animals and Induction of Experimental Lesions
Thirty (n=30) male New Zealand White rabbits (4.0±0.2 kg) were anesthetized by intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). After a high-cholesterol diet (2% cholesterol and 6% peanut oil for 28 days), atherosclerosis was induced by BI in femoral artery segments with or without prior EC injury by air desiccation with the use of nitrogen gas as described previously.23 24 25 Rabbits were assigned to 3 intervention groups: (1) non–cholesterol-fed (normal diet) rabbits (n=4) subjected to air desiccation EC injury only and analyzed 28 days after EC injury, (2) rabbits subjected to high-cholesterol diet without prior EC injury followed by BI (single-injury model) and analyzed 24 hours (n=4) or 28 days (n=5) after BI, and (3) rabbits subjected to BI after EC injury (double-injury model) and a high-cholesterol diet and analyzed 24 hours (n=7), 7 days (n=4), or 28 days (n=6) after BI. Control animals included uninjured rabbits fed a noncholesterol diet (normal diet, n=3) and uninjured rabbits fed a high-cholesterol diet (n=1). The control and intervention groups are shown in the Table
.
|
Balloon Injury
Details of the BI protocol have been published
previously.23 24 25 Briefly, BI was performed through a
right common carotid artery incision with a 2.5-mm-diameter balloon
dilation catheter (Advanced Cardiovascular Systems Inc)
after bolus heparin administration (150 U/kg, Solopak Laboratories).
Three 1-minute 10-atm inflations were performed 1 minute apart by use
of a hand inflator. After the procedure, the catheter was removed, the
carotid artery was ligated, and the wound was sutured. Rabbits were
then fed standard rabbit chow until the time of death. Animals were
administered an overdose of sodium pentobarbital, and the femoral
arteries were perfused at 100 mm Hg with 4%
paraformaldehyde in PBS through a catheter inserted in
the carotid artery and positioned above the aortoiliac bifurcation.
Segments of femoral arteries at the site of previous BI and/or EC
injury (2 to 3 cm in length) were excised, postfixed in 4%
paraformaldehyde in PBS, cross-sectioned at 2-mm
intervals, dehydrated in ethanol and xylene, and embedded in
paraffin.
Histomorphometry
Percent luminal cross-sectional area narrowing by plaque
(%CSAN-P) was determined by computerized planimetry with use of a
CUE-2 Image Analyzer (Galai Production Ltd) in
association with an Olympus BH-2 microprojection system as
described previously.26 %CSAN-P was calculated as the
area bound by the internal elastic lamina minus luminal area times 100
divided by the area bound by the internal elastic lamina.
Immunohistochemistry
Serial sections (5 µm) were cut onto
poly-L-lysine–coated slides (Sigma Chemical Co),
deparaffinized through ethanol and xylene, and rehydrated. Sections
were blocked with 2% horse serum in Tris-buffered saline for 1 hour at
37°C, washed with Tris-buffered saline, and incubated for 2 hours at
room temperature with primary antibody. mAb IG9 ascites (IgG3, 1:1000
dilution) was used to detect IG9 protein; RAM-11 mAb (mouse anti-rabbit
monocyte/macrophage antibody, IgG1, 1:50 dilution, Dako Corp)
was used for identification of monocytes; and mAb 1A4 (mouse anti-human
-smooth muscle actin, IgG2A, 1:200 dilution, Dako Corp) was used for
identification of SMCs. MCP-1 expression was detected with the mouse
anti-human mAb, 3F11 (IgG1, 1:200 dilution; a generous gift of Dr
Charles Mackay, formerly of Leukosite Inc, Cambridge, MA). After washes
with Tris-buffered saline, sections were incubated with biotinylated
horse anti-mouse IgG (1:800 dilution) for 1 hour, followed by a
45-minute incubation with avidin-biotin alkaline phosphatase (ABC
Vectastain, Vector Laboratories). The alkaline phosphatase substrate
consisted of nitro blue tetrazolium chloride and 5-bromo-4-chloro-3
indolyl phosphate p-toluidine salt (GIBCO-BRL) and 1
mmol/L levamisole (Sigma), an inhibitor of
endogenous alkaline phosphatase activity. Positive
reactivity is indicated by a blue-purple precipitate. Serial sections
from all intervention groups were also incubated with negative control,
isotype-matched, mouse myeloma proteins (IgG1, IgG2A, and IgG3,
Cappel-Organon Teknika Corp). Nonspecific antibody reactivity was not
detected in any of the sections.
Cell Culture
Human aortic SMCs were purchased from Clonetics or isolated from
human thoracic aortas harvested from explanted hearts at the time of
cardiac transplantation. Primary cultures were established by removing
the adventitia and connective tissue, dissecting the remaining
arterial intima and media into 1-cm2
segments, and incubating the tissue fragments in tissue culture dishes
with 2.5 mg/mL collagenase and 15% FBS. Adherent cells
were washed free of debris, and cells were grown in DMEM with 10% FBS,
50 U/mL penicillin, and 50 µg/mL streptomycin (Pen-Strep). Cells were
identified as SMCs by their typical microscopic appearance and by
immunostaining with antibody to -smooth muscle
actin. The absence of endothelial cell contamination
was confirmed by immunostaining with antibody F8/86 to
human von Willebrand factor (1:100 dilution, Dako Corp).
Growth Factors and Other Reagents
Recombinant human PDGF-BB homodimer, EGF, and interferon-
(IFN-, 200 IU/mL; endotoxin <0.2 ng/µg) were purchased from
Genzyme. Human TNF- (100 IU/mL, endotoxin <0.1 ng/µg) was
purchased from R&D Research Systems. DMEM, 100x Pen-Strep, and FBS
were purchased from GIBCO-BRL, and collagenase type II was
purchased from Worthington Biochemical.
Cell-Based ELISA
Human aortic SMCs were grown to confluence in 96-well culture
plates, and before treatment, SMCs (passages 7 to 12) were rendered
"quiescent" by incubation in low-serum medium consisting of
DMEM+1% FBS for 24 to 36 hours. Cells were treated (4 or 8 wells per
treatment) with TNF-, IFN-, EGF, or PDGF-BB for 4, 16, or 24
hours at 37°C and 5% CO2 in low-serum medium.
In addition, cells were treated with PDGF-BB in combination with
TNF-, IFN-, or EGF. SMCs were also pretreated with MM-LDL (250
µg/mL) for 24 hours in low-serum medium before cytokine
and/or growth factor treatment. LDL was isolated by density-gradient
centrifugation of serum and stored in PBS containing
0.01% EDTA. MM-LDL was obtained by storage of LDLs at 4°C for 3 to 6
months, as previously described,22 or by enzymatic
oxidation.27 Three to 5 separate experiments were
performed for each treatment group except for MM-LDL (n=2). Treated
SMCs were fixed in 2% formaldehyde in PBS, blocked with 1% BSA in
PBS, and incubated with mAb IG9 ascites (1:1000 dilution) for 2 hours
at 37°C. After PBS washes, alkaline phosphatase–coupled goat
anti-mouse IgG3 secondary antibody (1:1000 dilution, Southern
Biotechnologies) was added for 1 hour at 37°C, followed by the
addition of the alkaline phosphatase substrate p-nitrophenyl
phosphate disodium (Sigma). Absorbance was read at 405 nm. Results are
expressed as mean±SEM. Statistical significance was determined by
2-tailed Student t test. A value of P<0.05 was
considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
IG9 and MCP-1 Expression After EC Injury
Control femoral artery sections from non–cholesterol-fed (normal diet) uninjured rabbits lacked neointimal formation (%CSAN-P=0±0) and exhibited minimal to undetectable MCP-1, RAM-11(monocyte), or IG9 antibody reactivity (not shown). After cholesterol feeding for 28 days, femoral artery sections from an uninjured rabbit exhibited minimal to no neointimal formation; only small focal areas of luminal monocyte accumulation were detected. IG9 and MCP-1 expression was marginally elevated within the medial SMC layer of this vessel (not shown).
Femoral arteries subjected to air desiccation EC injury without subsequent high-cholesterol feeding exhibited mild to moderate neointimal formation (%CSAN-P=26±6) consisting almost entirely of SMCs, with monocyte infiltration localized to focal areas in the adventitia at 28 days after EC injury (not shown). All sections from this intervention group exhibited minimal to undetectable levels of IG9 and MCP-1 expression in the vessel wall (not shown).
IG9 and MCP-1 Expression After BI in
High-Cholesterol–Fed Rabbits (Single Injury)
Analysis of sections of arteries of
high-cholesterol–fed animals excised 24 hours after BI
(single injury) showed undetectable neointimal thickening
(%CSAN-P=0±0) with monocytes localized only to small focal
areas of the adventitia (Figure 1A).
Intense IG9 antibody reactivity was detected in medial SMCs in all
analyzed vessel sections (Figure 1B). Adventitial
microvessel SMCs also expressed high levels of IG9
immunostaining. MCP-1 antibody reactivity closely
paralleled that of mAb IG9 in intensity and localization (Figure 1C). IG9 and MCP-1 expression preceded detectable monocyte
infiltration of the tunica media and neointimal formation
in injured vessels. There were numerous IG9 (not shown) and
MCP-1–positive cells (Figure 1D) adherent to or just below the
internal elastic lamina, which were unreactive with the RAM-11
(monocyte) and 1A4 (SMC) antibodies. The identity of these cells is not
certain, but they could possibly be T lymphocytes, neutrophils, and/or
SMCs that have lost -smooth muscle actin expression.
|
Twenty-eight days after BI (single injury), significant
neointimal formation (%CSAN-P=50±4) consisting
of SMCs (Figure 2A) and monocytes (Figure 2B) was present. Substantial numbers of monocytes and
monocyte-derived foam cells (RAM-11 positive) were seen within the
media just below the internal elastic lamina and in the adventitia as
reported previously.28 Prominent IG9 and MCP-1
immunoreactivity was present in medial SMCs and to a lesser extent
in foam cells (Figure 2C and 2D). Adventitial microvessel SMCs
also showed marked IG9 and MCP-1 antibody reactivity.
Neointimal SMCs and monocytes were focally IG9 and MCP-1
positive (Figure 2C and 2D). A continuous layer of luminal
cells, probably ECs, were seen overlying plaques at this time point.
These cells expressed moderate to high levels of IG9 and MCP-1
immunoreactivity (Figure 2E and 2F) and were unreactive with the
RAM-11 (monocyte) and 1A4 (SMC) antibodies (not shown).
|
IG9 and MCP-1 Expression After EC Injury and BI in
High-Cholesterol–Fed Rabbits (Double Injury)
Substantial neointimal formation, consisting of SMCs
and monocytes, was detected in 6 of 7 animals analyzed 24 hours
after double injury (%CSAN-P=52±9), with numerous
monocytes and foam cells localized to the adventitia,
neointima, and the media below the internal elastic lamina
(Figure 3A) as reported
previously.24 25 26 28 29 In the 6 vessels with plaque
development, IG9 (Figure 3B) and MCP-1 (Figure 3C)
expression was localized to neointimal, medial, and
adventitial microvessel SMCs and to monocytes and foam cells within the
vessel wall and adventitia. IG9 immunoreactivity appeared less
prominent than that of MCP-1 in all of the analyzed vessel
sections.
|
The cell type–specific expression of IG9 did not change at 7 days
(%CSAN-P=29±3, not shown) and 28 days
(%CSAN-P=61±6, Figure 3E
) after double injury,
although IG9 immunoreactivity was greater than at 24 hours. In
addition, luminal ECs overlying the plaques were also moderately to
highly reactive with mAb IG9 (28 days after BI). MCP-1 expression at 7
days (not shown) and 28 days (Figure 3F) after BI (double
injury) was also very similar to that seen at 24 hours, with the
addition of luminal EC expression of MCP-1 28 days after BI.
Growth Factor, Cytokine, and MM-LDL Regulation of IG9
Expression in Human SMCs
The novel finding of SMC expression of IG9 after
cholesterol feeding and BI initiated a study to
characterize further the expression of the IG9 protein in this cell
type. Primary human aortic SMC cultures were treated with TNF-,
IFN-, EGF, or PDGF-BB. IG9 expression was analyzed by ELISA
after treatment for 4, 16, or 24 hours. Untreated SMCs expressed
minimal amounts of cell surface IG9 protein. Treatment with TNF- (1
to 500 U/mL), IFN- (1 to 1000 U/mL), EGF (1 to 30 ng/mL), or PDGF-BB
(1 to 50 ng/mL) for 4, 16, or 24 hours did not induce significant IG9
expression (data not shown). However, treatment with PDGF-BB (10 ng/mL)
in combination with IFN- (100 U/mL) or EGF (3 ng/mL) for 24 hours
induced significant IG9 expression compared with no treatment
(P<0.05, Figure 4).
|
We have previously shown that the proatherogenic oxidized lipid,
MM-LDL, at 250 µg/mL induces IG9 protein expression in human and
rabbit ECs after 24 hours and that this expression mediates a
significant portion of MM-LDL–induced monocyte
adhesion.20 To determine whether MM-LDL also induces IG9
expression in SMCs, cultures were treated with this concentration of
MM-LDL for 24 hours. Unlike ECs, IG9 expression was not significantly
induced in human aortic SMCs (Figure 5).
However, MM-LDL pretreatment of SMCs for 24 hours increased the level
of IG9 protein induced by TNF-, IFN-, EGF, or PDGF-BB, with
significant synergistic increases seen after treatment with EGF or
PDGF-BB in combination with TNF- or EGF (P<0.02 versus
no treatment, Figure 5; IFN- was not included in these
studies).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In the present study, we demonstrate that the IG9 monocyte adhesion protein is prominently expressed by SMCs within large areas of the tunica media as well as in adventitial microvessels 24 hours after a single BI of cholesterol-fed rabbit femoral arteries. This expression precedes the detectable influx of monocytes into the injured arterial vessel wall. The pronounced IG9 immunoreactivity, as well as that of MCP-1, detected in adventitial microvessels at this early time point is suggestive of adventitial contributions to lesion formation after arterial vessel injury. From previous immunohistochemical studies, it has been postulated that a large number of the foam cells in the neointima and media in this model of injury-induced atherogenesis are derived from cells of the media and adventitia rather than from the lumen.24 Support for this was derived from the finding of contiguity between neointimal and medial foam cells and those of the adventitia, with convincing evidence of association with neovasculature invasion from the adventitia. Thus, adventitial microvessel expression of a monocyte chemoattractant and a monocyte adhesion protein, as found in the present study, may establish an important route for monocyte trafficking from the adventitia into the injured vessel wall.
In a study by Scott et al,30 increased cell proliferation and growth factor synthesis in the adventitia were detected at early times after balloon overstretch injury of pig coronary arteries. Migration of adventitial myofibroblasts across the external elastic lamina to the developing neointima was demonstrated, and these results support the hypothesis that the adventitia may play a role in vascular lesion formation after vessel injury. In a recent report, enhanced leukocyte-endothelial cell interactions and P-selectin, ICAM-1, and VCAM-1 expression were found to occur in vivo in the rabbit mesenteric microcirculation during the first 2 weeks of hypercholesterolemia.31 The authors suggest that the microvasculature is an early site of vascular dysfunction, enabling circulating leukocytes to traffic from microvessels to large arterial vessels during plaque development. Thus, monocytes within the developing neointima and media of atherosclerotic vessels may not originate entirely from the lumen of the arterial vessel.
Neointimal formation 28 days after BI is characterized by significant monocyte accumulation throughout the vessel wall and is accompanied by prominent IG9 positivity on neointimal SMCs, monocytes, foam cells, and luminal ECs overlying the plaque. This is in contrast to the negligible monocyte accumulation that occurs 28 days after EC injury of normolipemic rabbit arteries and the minimal levels of IG9 expression in the fibrocellular lesions elicited by this type of vessel injury. The expression of IG9 on multiple cell types within the vessel wall at later time points after single BI is associated with marked monocyte infiltration into the neointima and media during injury-induced plaque progression and may result from the establishment of a lipid–, cytokine–, and growth factor–enriched microenvironment within the developing plaque.3 9 We demonstrate that cytokines and growth factors expressed in vivo during atherogenesis32 33 34 35 are inducers of IG9 expression in cultured SMCs and ECs. Thus, the expression of IG9 by multiple cell types within the vessel wall during injury-induced plaque progression may contribute to monocyte accumulation within the developing neointima, in addition to the media.
Our finding that IG9 is expressed in vivo by SMCs in the early response
to vessel injury initiated the study of the regulation of IG9
expression in this cell type. We found that TNF- did not induce IG9
expression in cultured human aortic SMCs, even though this
cytokine is a positive regulator of IG9 expression in
ECs.20 PDGF-BB or EGF, potent modulators of SMC
function,36 37 38 39 also did not induce significant IG9
expression in cultured SMCs. However, PDGF-BB in combination with EGF
or the activated T-lymphocyte product, IFN-, induced
significant IG9 protein expression. The regulation of IG9 protein
expression in SMCs may be dependent on activation of signaling pathways
by multiple growth factor and cytokine receptors to provide a
threshold level of protein expression that can be detected by mAb IG9.
Cytokine– and growth factor–induced IG9 expression in SMCs was upregulated by MM-LDL pretreatment. Oxidized lipoproteins are postulated to play a role in the development of atherosclerosis,40 41 42 and active oxidized phospholipids derived from MM-LDL were found to be increased in rabbit atherosclerotic lesions.43 Enhanced levels of MM-LDL within vessel walls may function as activators of SMCs and ECs because MM-LDL is mitogenic to cultured SMCs44 and induces MCP-1 in SMCs and ECs45 and macrophage colony–stimulating factor46 and tissue factor47 in ECs. In addition, MM-LDL also selectively stimulates ECs to bind monocytes,22 and this adhesion is dependent on MM-LDL–mediated increases in intracellular cAMP.27 MM-LDL–mediated signaling mechanisms in SMCs have not been extensively characterized to date, but the present study suggests that additive signal transduction pathways activated by cytokines, growth factors, and MM-LDL may significantly contribute to the induction of IG9 expression in SMCs. Another possibility is that MM-LDL may be modifying the plasma membrane, resulting in enhanced cytokine– and growth factor receptor–mediated induction of IG9 or in increased recognition of IG9 surface protein by mAb IG9 in treated SMCs.
IG9 expression in vivo at early time points after balloon
arterial injury in cholesterol-fed rabbits is
localized to vascular SMCs, and cytokines, growth factors, and
oxidized lipids associated with atherogenesis, including PDGF-BB,
IFN-, and MM-LDL, are potential inducers of IG9 expression in this
cell type. Therefore, our results suggest that IG9 is a cellular
adhesion molecule that contributes to the accumulation of monocytes
within the media of arterial vessels during the initiating
phase of injury-induced atherogenesis in cholesterol-fed
rabbits.
|
Acknowledgments |
|---|
This study was supported in part by US Public Health Service grant HL-30568 (J.A.B.), by National Institutes of Health grants HL-43302 (M.B.T.) and HL-54469 (M.B.T., J.T.F.), by the joint fund of the Israel Ministry of Science and Arts and the German Ministry of Science, Technology, and Education (BMBF, DISMED87/1338GR; S.D.G.), and by Grants-in-Aid from the American Heart Association, National Center (T.M.C., J.W.B., I.J.S.). We would like to thank Veronica Gulle, Louise S. Perez, Jason Cohen, and Lillie Lopez for their technical assistance.
Received June 18, 1999; accepted January 18, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Gerrity RG, Naito HK, Richardson M, Schwartz CJ. Dietary induced atherogenesis in swine: morphology of the intima in pre-lesion stages. Am J Pathol. 1979;95:775–786.[Medline] [Order article via Infotrieve]
2.
Faggiotto A, Ross R, Harker L. Studies of
hypercholesterolemia in the nonhuman primate,
I: changes that lead to fatty streak formation.
Arteriosclerosis. 1984;4:323–340.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990’s. Nature. 1993;362:801–809.[Medline] [Order article via Infotrieve]
4.
Hansson GK, Seifert PS, Olsson G, Bondjers G.
Immunohistochemical detection of macrophages and T lymphocytes
in atherosclerotic lesions of cholesterol-fed rabbits.
Arterioscler Thromb. 1991;11:745–750.
5. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol. 1990;65:297–302.[Medline] [Order article via Infotrieve]
6. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5–15.[Medline] [Order article via Infotrieve]
7.
Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T,
Yoshimura T, Leonard EJ, Witztum JL, Steinberg D. Expression of
monocyte chemoattractant protein 1 in macrophage-rich areas of
human and rabbit atherosclerotic lesions. Proc Natl Acad Sci
U S A. 1991;88:5252–5256.
8. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991;88:1121–1127.
9.
Ross R. Atherosclerosis: an
inflammatory disease. N Engl J Med.. 1999;340:115–126.
10. Mentzer SJ, Crimmins MAV, Burakoff SJ, Faller DV. Alpha and beta subunits of the LFA-1 membrane molecule are involved in human monocyte-endothelial cell adhesion. J Cell Physiol. 1987;130:410–415.[Medline] [Order article via Infotrieve]
11. Prieto J, Beatty PG, Clark EA, Patarroyo M. Molecules mediating adhesion of T and B cells, monocytes and granulocytes to vascular endothelial cells. Immunol. 1988;63:631–637.[Medline] [Order article via Infotrieve]
12. Springer TA. Adhesion receptors of the immune system. Nature. 1990;346:425–434.[Medline] [Order article via Infotrieve]
13.
Carlos TN, Kovach N, Schwartz B, Rosa M, Newman B,
Wayner E, Benjamin C, Osborn I, Lobb R, Harlan J. Human monocytes bind
to two cytokine-induced adhesive ligands on cultured human
endothelial cells:
endothelial-leukocyte adhesion molecule-1 and vascular
cell adhesion molecule-1. Blood. 1991;77:2266–2271.
14. Johnson-Tidey RR, McGregor JL, Taylor PR, Poston RN. Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques: coexpression with intercellular adhesion molecule-1. Am J Pathol. 1994;144:952–961.[Abstract]
15. Poston RN, Haskard DO, Coucher JR, Gall NP, Johnson-Tidey RR. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol. 1992;140:665–673.[Abstract]
16. Printseva OY, Peclo MM, Gown AM. Various cell types in human atherosclerotic lesions express ICAM-1. Am J Pathol. 1992;140:889–896.[Abstract]
17. van der Wal AC, Das PK, Tigges AJ, Becker AE. Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions. Am J Pathol. 1992;141:1427–1433.[Abstract]
18. Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, Kyriakopoulos A. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol. 1993;171:223–229.[Medline] [Order article via Infotrieve]
19. O’Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K, Benjamin CD, Lobb R, Alpers CE. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. J Clin Invest. 1993;92:945–951.
20. Calderon TM, Factor SM, Hatcher VB, Berliner JA, Berman JW. An endothelial cell adhesion protein for monocytes recognized by monoclonal antibody IG9. Lab Invest. 1994;70:836–849.[Medline] [Order article via Infotrieve]
21. Calderon TM, Kanaparti P, Lopez L, Berman JW. IG9 monocyte adhesion molecule expression is regulated by protein kinase C, receptor tyrosine kinase and anti-oxidant sensitive signal transduction pathways in vascular endothelial and smooth muscle cells. Circulation. 1996;94(suppl I):I-518. Abstract.
22. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest. 1990;85:1260–1266.
23.
Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER,
Roberts WC. Effectiveness of recombinant desulphatohirudin (CGP 39393)
in reducing restenosis after balloon angioplasty of
atherosclerotic femoral arteries in rabbits. Circulation. 1991;84:232–243.
24. Gertz SD, Gimple LW, Ragosta M, Roberts WC, Haber HL, Powers ER, Perez LS, Sarembock IJ. Response of femoral arteries of cholesterol-fed rabbits to balloon angioplasty with or without laser: emphasis on the distribution of foam cells. Exp Mol Pathol. 1993;59:225–243.[Medline] [Order article via Infotrieve]
25. Barry WL, Wiegman PJ, Gimple LW, Gertz SD, Powers ER, Owens GK, Sarembock IJ. A new single-injury model of balloon angioplasty in cholesterol-fed rabbits: beneficial effect of hirudin and comparison with double-injury model. Lab Invest. 1997;77:109–116.[Medline] [Order article via Infotrieve]
26. Gimple LW, Gertz SD, Haber HL, Powers ER, Roberts WC, Sarembock IJ. Effect of intramural or chronic subcutaneous administration of heparin on femoral artery restenosis following balloon angioplasty in rabbits: a quantitative angiographic and histopathologic study. Circulation. 1992;86:1535–1546.
27. Parhami F, Fang ZT, Fogelman AM, Andalibi A, Territo MC, Berliner JA. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J Clin Invest. 1993;92:471–478.
28.
Gertz SD, Barry WL, Gimple LW, Banai S, Perez LS,
McNamara CA, Powers ER, Ragosta M, Owens GK, Roberts WC, Sarembock IJ.
Predictors of luminal narrowing by neointima after
angioplasty in atherosclerotic rabbits. Cardiovasc Res. 1997;36:396–407.
29.
Wilensky RL, March KL, Gradus-Pizlo I, Sandusky G,
Fineberg N, Hathaway DR. Vascular injury, repair, and
restenosis after percutaneous transluminal
angioplasty in the atherosclerotic rabbit. Circulation. 1995;92:2995–3005.
30.
Scott NA, Ross CE, Dunn B, Martin FH, Simonet L, Wilcox
JN. Identification of a potential role for the adventitia in vascular
lesion formation after balloon overstretch injury of porcine
coronary arteries. Circulation. 1996;93:2178–2187.
31.
Scalia R, Appel JZ III, Lefer AM.
Leukocyte-endothelium interaction during the early
stages of hypercholesterolemia in the rabbit:
role of P-selectin, ICAM-1, and VCAM-1. Arterioscler Thromb Vasc
Biol. 1998;18:1093–1100.
32.
Barrett TB, Benditt EP. Platelet-derived growth
factor gene expression in human atherosclerotic plaques and normal
artery wall. Proc Natl Acad Sci U S A. 1988;85:2810–2814.
33. Wilcox JN, Smith KM, Williams LT, Schwartz SM, Gordon D. Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J Clin Invest. 1988;82:1134–1143.
34. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol. 1989;135:169–175.[Abstract]
35. Miyagawa J, Higashiyama S, Kawata S, Inui Y, Tamura S, Yamamoto K, Nishida M, Nakamura T, Yamashita S, Matsuzawa Y, et al. Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques. J Clin Invest. 1995;95:404–411.
36. Kariya K, Kawahara Y, Tsuda T, Fukuzaki H, Takai Y. Possible involvement of protein kinase C in platelet-derived growth factor-stimulated DNA synthesis in vascular smooth muscle. Atherosclerosis. 1987;63:251–255.[Medline] [Order article via Infotrieve]
37. Grotendorst GR, Chang T, Seppae HEJ, Kleinman HK, Martin GR. Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells. J Cell Physiol. 1981;113:261–266.
38.
Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA.
Role of platelets in smooth muscle cell proliferation and migration
after vascular injury in rat carotid artery. Proc Natl Acad Sci
U S A. 1989;86:8412–8416.
39. Bhargava G, Rifas L, Makman MH. Presence of epidermal growth factor receptors and influence of epidermal growth factor on proliferation and aging in cultured smooth muscle cells. J Cell Physiol. 1979;100:365–374.[Medline] [Order article via Infotrieve]
40.
Steinberg D, Witztum JL. Lipoproteins and
atherogenesis: current concepts. JAMA. 1990;264:3047–3052.
41. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785–1792.
42. Ross R. Atherosclerosis: a defense mechanism gone awry. Am J Pathol. 1993;143:987–1002.[Medline] [Order article via Infotrieve]
43.
Watson AD, Leitinger N, Navab M, Faull KF, Horkko S,
Witztum JL, Palinski W, Schwenke D, Salomon RG, Sha W, Subbanagounder
G, Fogelman AM, Berliner JA. Structural identification by mass
spectrometry of oxidized phospholipids in minimally oxidized low
density lipoprotein that induce monocyte/endothelial
interactions and evidence for their presence in vivo.
J Biol Chem. 1997;272:13597–13607.
44. Auge N, Pieraggi MT, Thiers JC, Negre-Salvayre A, Salvayre R. Proliferative and cytotoxic effects of mildly oxidized low-density lipoproteins on vascular smooth-muscle cells. Biochem J. 1995;309:1015–1020.
45.
Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab
M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified
low density lipoprotein induces monocyte chemotactic protein 1 in human
endothelial cells and smooth muscle cells. Proc
Natl Acad Sci U S A. 1990;87:5134–5138.
46. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, Lusis AJ. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature. 1990;344:254–257.[Medline] [Order article via Infotrieve]
47. Drake TA, Hannani K, Fei HH, Lavi S, Berliner JA. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am J Pathol. 1991;138:601–607.[Abstract]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||